Loading stock data…
Assembly Biosciences, Inc. (ASMB)
$36.60+0.47 (+1.30%)
Pre-Market$36.75+0.15 (+0.41%)· Last close Sep 4
Assembly Biosciences, Inc., a biotechnology company, develops therapeutic candidates for the treatment of viral diseases worldwide.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Assembly Biosciences, Inc. in the Healthcare sector is trading at $36.60 with a market capitalization of $487M. Wall Street consensus targets $52.00 (5 analysts), implying a +42.1% move over the next 12 months. The stock is currently near its 52-week high of $39.71, remaining 24.9% above its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality. The Whystock Score of 95/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +42.1% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $8.21M↓ | $42.47M↑ | $10.79M↑ | $9.63M↑ | $9.42M |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$11.37M↓ | $19.80M↑ | -$10.88M↑ | -$11.09M↓ | -$9.94M |
| Net Income | -$9.08M↓ | $22.09M↑ | -$9.20M↑ | -$10.20M↓ | -$8.82M |
Peer Comparison
JNJUNHPFE
Fundamentals
Assembly Biosciences, Inc., a biotechnology company, develops therapeutic candidates for the treatment of viral diseases worldwide. Its pipeline includes long-acting helicase-primase inhibitors candidates, including ABI-5366 and ABI-1179, which are i...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$486.91M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
307.13
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.09
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-3.21%
Volume
Today's trading volume
156,451
Recent News
Wall Street Analysts See a 35.71% Upside in Assembly Biosciences (ASMB): Can the Stock Really Move This High?
The average of price targets set by Wall Street analysts indicates a potential upside of 35.7% in Assembly Biosciences (ASMB). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Should You Buy Assembly Biosciences (ASMB) After Golden Cross?
Good things could be on the horizon when a stock experiences a golden cross event. How should investors react?
5 Stocks With Recent Price Strength Buoyed by a Strong August
EDRY, RCMT, ASMB, DCTH and NESR show strong recent price momentum after a strong August, backed by improving earnings expectations.
Here's Why Momentum in Assembly Biosciences (ASMB) Should Keep going
Assembly Biosciences (ASMB) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
Best Momentum Stocks to Buy for August 25th
LQDT, IA and ASMB made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on August 25th, 2026.